✨ Free AI Report
ResMed Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research ResMed Inc.
Company Research

ResMed Inc.: Business Overview, Financials & Competitive Analysis

ResMed Inc. scores 8/10 on the AskCyborg Cyborg Score (Strong). ResMed is a well-positioned healthcare medtech leader with durable competitive advantages, strong margin expansion, and consistent profitability growth in attractive end markets. The company delivered 11% headline revenue growth with 310 basis points of non-GAAP gross margin expansion in Q2 FY2026, resulting in mid-teens non-GAAP EPS growth. ResMed's free cash.

What is ResMed Inc.'s industry? ResMed Inc. (resmed.com) operates in Medical Devices & Digital Health Technology. AskCyborg classifies ResMed Inc. under Medical Devices & Digital Health Technology in its company registry.

ResMed develops cloud-connected medical devices and software solutions that treat sleep apnea, COPD, and other respiratory disorders for home and clinical use. By enabling better care, ResMed improves quality of life,...

8/ 10Strong

Cyborg Score thesis

ResMed is a well-positioned healthcare medtech leader with durable competitive advantages, strong margin expansion, and...

Read the full analyst-debate transcript →
Industry Medical Devices & Digital Health Technology
4 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest ResMed Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for ResMed Inc.

AskCyborg analysts argue the bull and bear cases for ResMed Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
ResMed Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

ResMed Inc. Overview

Pro stress-test →

ResMed develops cloud-connected medical devices and software solutions that treat sleep apnea, COPD, and other respiratory disorders for home and clinical use. By enabling better care, ResMed improves quality of life, reduces the impact of chronic disease, and lowers costs for consumers and healthcare systems in more than 140 countries.

Strategic Profile

Pro stress-test →

The company's strategy focuses on transforming healthcare in the home with hardware, software and solutions that people love. ResMed's EPS grew at a 14.2% compounded annual growth rate over five years, higher than its 11.8% annualized revenue growth, demonstrating strong profitability expansion. With a notable 66.4% Return on Invested Capital, ResMed demonstrates management's strong skill in using capital for high-return growth, indicating a lasting competitive edge.

Competitive Landscape

Pro stress-test →

ResMed operates in the digital health and cloud-connected medical device space for treating sleep apnea, COPD, and other chronic diseases. The company faces competition from other respiratory device manufacturers and digital health software providers, but maintains leadership through its integrated portfolio spanning devices, masks, and cloud-based care management platforms across multiple geographic markets.

Industry Context

ResMed Inc. operates in Medical Devices & Digital Health Technology.

Key facts

Founded: 1989 · Headquarters: San Diego, United States · Employees: 32000 · Revenue: $5.4B · Market cap: $36.78B

What the analysts stress-tested

The top findings that survived the multi-agent debate for ResMed Inc..

  • In Q1 FY2026, ResMed delivered 9% headline revenue growth with 280 basis points of non-GAAP gross margin expansion and 16% non-GAAP EPS growth.
  • ResMed is strategically expanding its mask portfolio with new product innovations, including the launch of two new full-face fabric masks.
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Q2 FY2026 earnings announced with 11% headline revenue growth and 310 basis points gross margin expansion
  • January 2026Analyst price target increases from KeyBanc and RBC Capital Markets citing strong earnings and solid performance
  • +1 moreTrack every material event for ResMed Inc. as it happens. Explore monitoring →
Get alerted when ResMed Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Philips RespironicsSleep and respiratory care devices→GE HealthcareRespiratory and monitoring solutions→Fisher & PaykelHumidification and respiratory care devices→SleepApnea.comOnline sleep apnea retail platform→

Compare ResMed Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

ResMed Inc. operates in Medical Devices & Digital Health Technology. See how the rest of the sector scores on the Cyborg framework.

Browse Medical Devices & Digital Health Technology research →
NEW · MCP server

Ask your AI assistant about ResMed Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare ResMed Inc. and its top competitor on Cyborg Score”
“What did ResMed Inc. do this quarter?”
“Is ResMed Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does ResMed Inc. do?+
ResMed develops cloud-connected medical devices and software solutions that treat sleep apnea, COPD, and other respiratory disorders for home and clinical use. By enabling better care, ResMed improves quality of life,...
What is ResMed Inc.'s Cyborg Score?+
ResMed Inc. has a Cyborg Score of 8/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are ResMed Inc.'s main competitors?+
Named competitors include Philips Respironics, GE Healthcare, Fisher & Paykel, SleepApnea.com. The full competitive landscape is in the AskCyborg report.
How can I get the full ResMed Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the ResMed Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track ResMed Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.